Altamira Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Altamira Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 23.6% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID
Sep 13Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio
Aug 30Altamira starts development program for potential arthritis therapy
Jul 25Altamira announces peer-reviewed publication on mRNA delivery platform
Jul 19Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform
Jul 12Auris Medical shares rise on OligoPhore Lymphoma study results
Jun 21Auris Medical starts preparations for COVID-19 trial with Bentrio in India
Jun 01Auris Medical updates on pollen challenge study for nasal spray
May 10Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?
Dec 09
Auris Medical prices $8M direct equity offering, stock -22%
Dec 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | N/A | N/A | N/A | 1 |
| 12/31/2025 | N/A | N/A | N/A | N/A | 1 |
| 12/31/2024 | N/A | N/A | N/A | N/A | 1 |
| 12/31/2023 | N/A | -7 | -12 | -12 | N/A |
| 6/30/2023 | 0 | -24 | -11 | -11 | N/A |
| 3/31/2023 | 0 | -25 | -11 | -10 | N/A |
| 12/31/2022 | N/A | -19 | -11 | -9 | N/A |
| 9/30/2022 | 0 | -23 | -14 | -12 | N/A |
| 6/30/2022 | 0 | -19 | -17 | -14 | N/A |
| 3/31/2022 | 0 | -18 | -17 | -14 | N/A |
| 12/31/2021 | N/A | -7 | -17 | -14 | N/A |
| 9/30/2021 | 0 | -15 | -14 | -11 | N/A |
| 6/30/2021 | N/A | -12 | -12 | -8 | N/A |
| 3/31/2021 | N/A | -10 | -9 | -6 | N/A |
| 12/31/2020 | N/A | -8 | -7 | -5 | N/A |
| 9/30/2020 | N/A | -7 | -7 | -5 | N/A |
| 6/30/2020 | N/A | -6 | -7 | -5 | N/A |
| 3/31/2020 | N/A | -6 | -9 | -7 | N/A |
| 12/31/2019 | N/A | -7 | -11 | -8 | N/A |
| 9/30/2019 | N/A | -9 | -13 | -9 | N/A |
| 6/30/2019 | N/A | -10 | -15 | -11 | N/A |
| 3/31/2019 | N/A | -12 | -14 | -11 | N/A |
| 12/31/2018 | N/A | -11 | -15 | -13 | N/A |
| 9/30/2018 | N/A | -12 | -18 | -18 | N/A |
| 6/30/2018 | N/A | -15 | -19 | -18 | N/A |
| 3/31/2018 | N/A | -18 | -23 | -22 | N/A |
| 12/31/2017 | N/A | -24 | -24 | -24 | N/A |
| 9/30/2017 | N/A | -25 | N/A | -24 | N/A |
| 6/30/2017 | N/A | -27 | N/A | -26 | N/A |
| 3/31/2017 | N/A | -30 | N/A | -29 | N/A |
| 12/31/2016 | N/A | -31 | N/A | -29 | N/A |
| 9/30/2016 | N/A | -31 | N/A | -30 | N/A |
| 6/30/2016 | N/A | -28 | N/A | -31 | N/A |
| 3/31/2016 | N/A | -31 | N/A | -30 | N/A |
| 12/31/2015 | N/A | -30 | N/A | -29 | N/A |
| 9/30/2015 | N/A | -28 | N/A | -27 | N/A |
| 6/30/2015 | N/A | -26 | N/A | -22 | N/A |
| 3/31/2015 | N/A | -20 | N/A | -22 | N/A |
| 12/31/2014 | N/A | -18 | N/A | -19 | N/A |
| 9/30/2014 | N/A | -18 | N/A | -19 | N/A |
| 6/30/2014 | N/A | -19 | N/A | -20 | N/A |
| 3/31/2014 | N/A | -19 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CYTO's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if CYTO's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CYTO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CYTO's revenue is forecast to grow faster than the US market.
High Growth Revenue: CYTO is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYTO's Return on Equity is forecast to be high in 3 years time